eligibility_summary
Eligibility: Phase 1—refractory advanced solid tumors, Phase 2—selected refractory solid tumors (per Phase 1). Prior TROP2 therapy allowed. Needs measurable disease, ECOG 0–1, adequate organs (ANC ≥1.5, Plt ≥100, Hgb ≥9, AST/ALT ≤2.5×ULN or ≤5× with liver mets), and tumor tissue/biopsies (mandatory in some cohorts). Exclude active/progressing CNS or LMD (stable/treated CNS mets may qualify), systemic therapy within 5 half-lives/4 wks, >Grade 1 toxicities, or steroids >10 mg/d.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05941507 tests LCB84, a TROP2-directed antibody-drug conjugate (human mAb linked to the microtubule inhibitor prodrug MMAE), as monotherapy and combined with an anti-PD-1 monoclonal antibody in advanced solid tumors. Mechanisms: LCB84 binds TROP2 on tumor cells, is internalized, and releases MMAE to disrupt microtubules and induce apoptosis (with potential bystander/immunogenic effects). The anti-PD-1 agent blocks the PD-1 checkpoint to reinvigorate cytotoxic T-cell activity. Targets: TROP2-overexpressing epithelial tumor cells, microtubule cytoskeleton, and the PD-1 pathway on exhausted T cells.